Biotech Gets a Strong Buy from S&P
The outlook for biotech stocks got a boost from Standard & Poor’s Equity Research team which recently upgraded its outlook for the industry to positive from neutral.
S&P recently upgraded Gilead Sciences (GILD), Celgene (CELG), and Vertex (VRTX). Three ETFs that hold at least one of these stocks include iShares Dow Jones U.S. Healthcare (IYH), Health Care Select Sector SPDR (XLV), and Vanguard Health Care (VHT).


